ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
The only available trial, a non-comparative study with 63 patients, failed to determine the efficacy of ibrutinib. In contrast, adverse effects are numerous and sometimes severe, including haematological disorders. Further evaluation of ibrutinib in this setting is necessary.